<DOC>
	<DOCNO>NCT02639130</DOCNO>
	<brief_summary>To determine extent effect treatment LAF237 100 mg QD glucagon secretion mediate Glucagon-like-peptide 1 ( GLP-1 ) type 2 diabetic patient healthy subject .</brief_summary>
	<brief_title>GLP-1 Mediating DPP-4 Inhibition Type 2 Diabetes</brief_title>
	<detailed_description>Design : This two center study employ double blind , placebo control , cross-over study patient type 2 diabetes ( T2D ) healthy volunteer comparable age , gender BMI distribution . Subjects ( 40 patient 40 healthy volunteer , referred subject remain part document ) randomize 100 mg LAF 237 QD placebo two 10-day treatment period cross-over design . Thirty two ( 32 ) efficacy evaluable patient require complete study . Each subject participate approximate 14-day screening period , 2-week wash-out period metformin , 1-day baseline period 10-day treatment period follow 2-4 week wash-out period second treatment period . An end study evaluation conduct follow completion second treatment period event early withdrawal termination patient . At screen , subject meet inclusion/exclusion criterion begin weight maintenance diet contain 50 % carbohydrate , 30 % protein 20 % fat . Patients receive guidance dietary maintenance screen stay diet screen end study evaluation . Following screen visit , enrol patient start 2 week drug wash-out period oral hypoglycemic medication discontinue . During drug wash-out period , patient monitor glucose level two time day ( prior breakfast dinner ) use glucometer . Additionally , one week interval , patient perform seven point blood glucose test , glucose measurement make prior two hour meal , prior bed . Weekly telephone call make patient , result glucose test record . Patients discontinue study wash-out period fast glucose level exceed 200 mg/dl two consecutive measurement .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Treatment either diet/exercise metformin HbA1c 6.5 9.0 % Fasting plasma glucose 6.0 11.0 mmol/l Bodymassindex 20.0 35.0 kg/m² Healthy control require normal oral glucose tolerance test ( 75g ) firstdegree relatives type 2 diabetes personal history gestational diabetes Significant heart , kidney ( serum creatinine ≤ 123 µmol/l woman ≤ 132 µmol/l men ) , liver ( transaminase &lt; 2fold upper limit normal ) gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gastric Inhibitory Polypeptide ( GIP )</keyword>
	<keyword>Glucagon-Like Peptide 1 ( GLP-1 )</keyword>
	<keyword>DPP-4 inhibition ; Exendin [ 9-39 ]</keyword>
	<keyword>Gastric empty</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Incretin</keyword>
	<keyword>Insulin Secretion</keyword>
	<keyword>Normal glucose-tolerant</keyword>
</DOC>